Wednesday 10 and Thursday 11 September 2008, Berlin, Germany
The future of the pharmaceutical industry lies with biotechnology. Biotech drugs account for around 10-15% of the current pharmaceutical market, and the sector is outperforming the market as a whole in terms of growth. With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive.
The 2nd annual Biosimilars Conference will bring experts from the industry and academy sector together to discuss the latest developments in biosimilars regulations, clinical assessment, manufacturing processes and pricing and reimbursement. Through a series of presentations and interactive discussions, participants will gain new insight and share hands-on experiences in the latest trends and practices in the development of biosimilars.
|
